Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers
This study underscored the clinical and genomic heterogeneity of GI-NEC and highlighted the need to integrate genomic and clinical data to achieve personalized medicine. <i>MYC</i> amplification and <i>KRAS</i> alterations may serve as valuable predictors of treatment response and prognosis in patients with GI-NEC.
Authors
- Yoshiyasu Kono (ORCID: https://orcid.org/0000-0002-4717-5196)
- Toshiki Ozato (ORCID: https://orcid.org/0009-0003-9738-8768)
- S. Toyooka
- Motoyuki Otsuka (ORCID: https://orcid.org/0000-0003-2869-2881)
- Daisuke Ennishi (ORCID: https://orcid.org/0000-0003-4788-2103)
- S. Tomida
- Akira Hirasawa (ORCID: https://orcid.org/0000-0003-4124-5488)
- Hideki Yamamoto (ORCID: https://orcid.org/0000-0003-4919-3483)
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100193
- Citations
- 2
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Mitsubishi Foundation
- Foundation for Promotion of Cancer Research